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INTRODUCTION: Eighty to ninety percent
of APAP is metabolized by glucuronidation
and sulfation and excreted in urine. The
remaining 5-10% of APAP is metabolized by
CYP450/CYP2E
into
N-acetyl-pbenzoquinone imine (NAPQI), the toxic
metabolite
responsible
for
APAP
hepatotoxicity.3 NAPQI is inactivated when
conjugated to tripeptide glutathione. During
APAP overdose, excessive quantities of
NAPQI and depleted glutathione stores lead
to hepatotoxicity.3 There exists only two case
reports on hepatotoxicity associated with
therapeutic doses of IV APAP in postoperative patients with native livers,
however, one was confounded by postoperative shock liver.4,5 There is no validated
nomogram to guide treatment of IV APAP
overdose or toxicity. NAC therapy remains
the mainstay for PO APAP overdose.
CASE REPORT: A 69 year old male with a
past medical history of secondary biliary
liver cirrhosis status post orthotopic liver
transplantation in 2006, Hepatocellular
carcinoma of the explanted liver, splenic
artery aneurysm status post splenectomy and
newly diagnosed prostate adenocarcinoma
was admitted to the Urology service for
planned robotic-assisted prostatectomy.
Eighteen days prior to presentation, the
patient was medically cleared by Transplant
Hepatology for prostatectomy. He was noted
_________________
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to have a normal functioning hepatic graft
and advised to continue taking tacrolimus 0.5
mg
twice
daily.
At
that
time,
aminotransferase (AST) was 23 IU/L, alanine
aminotransferase (ALT) 24 IU/L, total
bilirubin (TBili) 1.4 mg/dL, and international
normalized ratio (INR) 1.0.
He underwent uncomplicated roboticassisted prostatectomy, requiring no fluid
resuscitation, vasopressor support or blood
products. Post-operatively, vital signs
remained normal with no episodes of
hypotension. Physical exam was notable for
mild tenderness to palpation around the
laparoscopic incision sites. He was started on
a clear liquid diet and IV APAP 1000 mg
every 6 hours for 36 hours, followed by PO
APAP 650 mg every 6 hours for postoperative pain.
On post-operative day 1, AST was 2275
IU/L, ALT 2521 IU/L, TBili 1.3 mg/dL, and
INR 1.4. On post-operative day 2, AST was
2751 IU/L, ALT 3447 IU/L, TBili 1.9 mg/dL
and INR 1.5 (Figure 1).

Figure 1. AST, ALT, Total Bilirubin Levels
Before, During, and After Hospital
Admission
The patient developed a diffuse, pruritic
maculopapular rash around his torso and
bilateral upper arms, unrelieved by oral
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diphenhydramine.
All
orders
for
acetaminophen were stopped. Liver Doppler
ultrasound was normal. By this time, the
patient had received 5000 mg of IV APAP
and 650 mg of PO APAP total. A serum
acetaminophen level was drawn 10 hours
after the last IV APAP dose and noted to be
< 15 ug/mL. Hepatology was consulted.
The patient reported consuming daily herbal
supplements for the past 14 months,
including saw palmetto, pygeum, cranberry
extract, pumpkin seed extract and betasitosterol. He stopped taking the herbal
supplements 7 days prior to the
prostatectomy. He denied alcohol use and
reported minimal nausea, but no vomiting.
His average daily intake was 3.5 liters. Work
up for infectious etiologies was negative.
The patient was started on IV NAC, with a
loading dose of 150 mg/kg followed by a
maintenance dose of 50 mg/kg over 4 hours,
then 100 mg/kg over 16 hours. Within 18
hours, AST was 1350 IU/L, ALT 2836 IU/L,
and INR 1.5. TBili increased to 2.4 mg/dL.
Following completion of IV NAC therapy,
AST was 986 IU/L, ALT 2340 IU/L, TBili
1.9 mg/dL, and INR 1.4. His macular papular
rash resolved during IV NAC therapy.
The patient was discharged home on postoperative day 4. Labs during his outpatient
Hepatology follow-up appointment 4 days
after discharge were AST 62 IU/L, ALT 426
IU/L, TBili 1.3 mg/dL, and INR 1.1.
DISCUSSION: This is the first case of acute
liver toxicity in a post-OLT patient who
received therapeutic doses of IV APAP
subsequently responded to IV NAC therapy.
The patient's AST, ALT, TBili and INR were
normal prior to IV APAP exposure.
Elevations in AST, ALT, TBili, and INR
improved after IV APAP was discontinued
and IV NAC initiated. A serum APAP level
drawn 10 hours after the last IV APAP
administration was < 15 ug/mL, consistent
with therapeutic dosage. There was no
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evidence of hypotension or APAP overdose
in the electronic medical records. All other
etiologies for acute liver toxicity were ruled
out, including shock liver, infection and
vascular compromise.
Risk factors that have been shown to increase
the risk of hepatotoxicity in APAP overdose
patients include malnutrition, eating
disorders, AIDS, alcoholism, antiepileptic
medications, and tuberculosis medications.6
Our patient did not have any of these risk
factors. Although he experienced nausea
post-operatively, daily total intake was
adequate and there were no periods of fasting
or malnutrition. It is unlikely the patient's
hepatotoxicity was due to herbal drug
induced liver injury or herbal-drug
interactions with IV APAP. Case reports
exist on saw palmetto associated cholestatic
hepatotoxicity.7 However, prospective trials
have found little evidence of liver injury
linked to saw palmetto.8 There was no
history of hepatotoxicity during the 14
months that the patient consumed saw
palmetto and he ceased saw palmetto
consumption 7 days prior to admission.
Online Pubmed literature searches on
hepatotoxicity due to pygeum, cranberry
extract, pumpkin seed extract or betasitosterol did not yield results.
The patient's transplant liver may have been
predisposed to IV APAP toxicity, even at
therapeutic doses. It is possible APAP
metabolism is altered in transplant livers
compared to native livers. A study on 13 liver
transplant patients concluded APAP
metabolism was transiently altered in
orthotopic
livers
following
liver
transplantation, resulting in enhanced
NAPQI production.9 Liver Transplant
Centers in the Scientific Registry of
Transplant Recipients have issued post-OLT
guidebooks for patients, recommending no
more than 1500 mg to 2000 mg of PO APAP
daily, lower than the daily maximum limit of
4000 mg.10,11,12 Furthermore, studies show
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decreased glutathione levels in transplant
livers after undergoing pre-transplant cold
storage preservation and post-transplant
reperfusion. It is possible transplant livers
carry less glutathione stores, rendering them
more susceptible to hepatotoxicity from
NAPQI concentrations that a native liver
would tolerate.13 Further studies on what is
considered safe, therapeutic IV APAP dosing
in post-OLT patients is needed to prevent
hepatotoxicity in this patient population.
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